We investigated the effects of two FDA-approved metabolic agents—Alirocumab, a PCSK9 inhibitor that lowers LDL cholesterol, and Gliclazide, a sulfonylurea that enhances insulin secretion—in male 5xFAD mice, a transgenic model of AD. The gene discussed is INS; the disease is Alzheimer disease.